Merck and Terns Pharmaceuticals have agreed to a $6.7 billion all-cash buyout that delivers a prized leukemia asset to the ...

Some investors and analysts believe the pharma’s $6.7 billion offer is justified given Terns’ recent stock run. Others are ...

It is important to distinguish de novo CML-BP from Ph-positive ALL before allogeneic hematopoietic cell transplantation. The effect of BCR::ABL1 mutation status on outcomes of hematopoietic cell ...

Merck & Co. has agreed to acquire Terns Pharmaceuticals for approximately $6.7 billion, in a deal designed to bolster the buyer’s cancer pipeline with that of Terns—led by an oral tyrosine kinase ...

According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases of the ...

A panel of experts on introduce a discussion on chronic myeloid leukemia (CML) with an overview of the disease, focusing on its subtypes and characteristics. Please provide some background on CML.

Tyrosine kinase inhibitors (TKIs) have revolutionized CML treatment, offering more effective and better-tolerated options than previous therapies. Second- and third-generation TKIs address resistance ...

"I know physicians are busy, but I’m treating a patient, not a disease. I take a holistic approach. I think we need to make physicians who treat chronic myeloid leukemia treat the disease and make ...

The MarketWatch News Department was not involved in the creation of this content. 64% MMR achievement by 24 weeks across all efficacy evaluable patients 75% MMR achievement by 24 weeks in efficacy ...

Chronic myeloid leukemia (CML) is a hematopoietic malignancy characterized by BCR-ABL1 gene fusion. The immune microenvironment, implicated in relapse and drug resistance, poses significant challenges ...